Gowtham A, Chauhan Chandan, Rahi Vikrant, Kaundal Ravinder K
Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research, Lucknow, India.
Expert Opin Ther Targets. 2024 Dec;28(12):1149-1175. doi: 10.1080/14728222.2024.2446319. Epub 2024 Dec 25.
Ischemic stroke (IS), a major cause of mortality and disability worldwide, remains a significant healthcare challenge due to limited therapeutic options. Ferroptosis, a distinct iron-dependent form of regulated cell death characterized by lipid peroxidation and oxidative stress, has emerged as a crucial mechanism in IS pathophysiology. This review explores the role of ferroptosis in IS and its potential for driving innovative therapeutic strategies.
This review delves into the practical implications of ferroptosis in IS, focusing on molecular mechanisms like lipid peroxidation, iron accumulation, and their interplay with inflammation, reactive oxygen species (ROS), and the Nrf2-ARE antioxidant system. It highlights ferroptotic proteins, small-molecule inhibitors, and non-coding RNA modulators as emerging therapeutic targets to mitigate neuroinflammation and neuronal cell death. Studies from PubMed (1982-2024) were identified using MeSH terms such as 'Ferroptosis' and 'Ischemic Stroke,' and only rigorously screened articles were included.
Despite preclinical evidence supporting the neuroprotective effects of ferroptosis inhibitors, clinical translation faces hurdles such as suboptimal pharmacokinetics and safety concerns. Advances in drug delivery systems, bioinformatics, and AI-driven drug discovery may optimize ferroptosis-targeting strategies, develop biomarkers, and improve therapeutic outcomes for IS patients.
缺血性中风(IS)是全球死亡和残疾的主要原因,由于治疗选择有限,仍然是一个重大的医疗挑战。铁死亡是一种独特的铁依赖性调节性细胞死亡形式,其特征是脂质过氧化和氧化应激,已成为IS病理生理学中的关键机制。本综述探讨了铁死亡在IS中的作用及其推动创新治疗策略的潜力。
本综述深入探讨了铁死亡在IS中的实际意义,重点关注脂质过氧化、铁积累等分子机制,以及它们与炎症、活性氧(ROS)和Nrf2-ARE抗氧化系统的相互作用。它强调铁死亡相关蛋白、小分子抑制剂和非编码RNA调节剂是减轻神经炎症和神经元细胞死亡的新兴治疗靶点。使用“铁死亡”和“缺血性中风”等医学主题词在PubMed(1982 - 2024年)中检索研究,仅纳入经过严格筛选的文章。
尽管临床前证据支持铁死亡抑制剂的神经保护作用,但临床转化面临药代动力学欠佳和安全性问题等障碍。药物递送系统、生物信息学和人工智能驱动的药物发现方面的进展可能会优化针对铁死亡的策略,开发生物标志物,并改善IS患者的治疗效果。